T1	PROC 45 59	Ensayo Clínico
#1	AnnotatorNotes T1	C0008976; Clinical Trials; Research Activity
T2	PROC 93 101	terapias
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	CHEM 103 120	ácido hialurónico
#3	AnnotatorNotes T3	C0020196; hyaluronic acid; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T4	CHEM 121 139	condroitín sulfato
#4	AnnotatorNotes T4	C0008466; chondroitin sulfates; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T5	CHEM 144 166	fosfomicina trometamol
#5	AnnotatorNotes T5	C0543454; fosfomycin tromethamine; Antibiotic · Organic Chemical
T6	PROC 174 184	prevención
#6	AnnotatorNotes T6	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T7	DISO 192 200	cistitis
#7	AnnotatorNotes T7	C0010692; Cystitis; Disease or Syndrome
T8	PROC 236 299	Ensayo clínico multicéntrico en fase IV, aleatorizado, paralelo
T9	PROC 306 325	valorar la eficacia
#8	AnnotatorNotes T9	C1707887; Efficacy Study; Research Activity
T10	CHEM 330 347	Ácido Hialurónico
#9	AnnotatorNotes T10	C0020196; hyaluronic acid; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T11	CHEM 348 366	Condroitín Sulfato
#10	AnnotatorNotes T11	C0008466; chondroitin sulfates; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T12	CHEM 376 398	Fosfomicina trometamol
#11	AnnotatorNotes T12	C0543454; fosfomycin tromethamine; Antibiotic · Organic Chemical
T13	PROC 405 415	prevención
#12	AnnotatorNotes T13	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T14	DISO 423 444	Infecciones Urinarias
#13	AnnotatorNotes T14	C0042029; Urinary tract infection; Disease or Syndrome
T15	DISO 481 489	Cistitis
#14	AnnotatorNotes T15	C0010692; Cystitis; Disease or Syndrome
T16	DISO 530 561	Infecciones del tracto urinario
#15	AnnotatorNotes T16	C0042029; Urinary tract infection; Disease or Syndrome
T17	ANAT 546 561	tracto urinario
#16	AnnotatorNotes T17	C0042027; Urinary tract; Body Part, Organ, or Organ Component | C1280341; Entire urinary tract; Body System
T18	DISO 633 653	infecciones de orina
T19	PROC 686 702	cultivo de orina
#17	AnnotatorNotes T19	C0430404; Urine culture; Laboratory Procedure
T20	PROC 741 757	Cultivo de orina
#18	AnnotatorNotes T20	C0430404; Urine culture; Laboratory Procedure
T21	ANAT 752 757	orina
#19	AnnotatorNotes T21	C0042036; Urine; Body Substance
T22	PROC 875 896	método anticonceptivo
#20	AnnotatorNotes T22	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T23	PROC 1074 1110	consentimiento informado por escrito
#21	AnnotatorNotes T23	C0811741; Obtain informed written consent; Health Care Activity
T24	PROC 931 954	métodos anticonceptivos
#22	AnnotatorNotes T24	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T25	PROC 1018 1028	vasectomía
#23	AnnotatorNotes T25	C0042387; Vasectomy; Therapeutic or Preventive Procedure
T26	CHEM 1031 1057	anticonceptivos hormonales
T27	DISO 1150 1159	infección
#24	AnnotatorNotes T27	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T28	DISO 1204 1226	infección por gérmenes
T29	CHEM 1241 1263	fosfomicina trometamol
#25	AnnotatorNotes T29	C0543454; fosfomycin tromethamine; Antibiotic · Organic Chemical
T30	PROC 1267 1303	Tratamiento antibiótico profiláctico
#26	AnnotatorNotes T30	C0282638; Antibiotic Prophylaxis; Therapeutic or Preventive Procedure
T31	CHEM 1279 1290	antibiótico
#27	AnnotatorNotes T31	C0003232; Antibiotics; Antibiotic
T32	PROC 1337 1348	Tratamiento
#28	AnnotatorNotes T32	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T33	CHEM 1353 1355	AH
#29	AnnotatorNotes T33	C0020196; hyaluronic acid; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T34	CHEM 1356 1358	CS
#30	AnnotatorNotes T34	C0008466; chondroitin sulfates; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T35	PROC 1463 1472	ecografía
T36	ANAT 1508 1515	vesical
#31	AnnotatorNotes T36	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T37	DISO 1529 1542	tumor vesical
T38	DISO 1544 1560	litiasis vesical
#32	AnnotatorNotes T38	C0005683; Urinary Bladder Calculi (disorder); Disease or Syndrome
T39	DISO 1568 1584	Vejiga neurógena
#33	AnnotatorNotes T39	C0005697; Neurogenic Urinary Bladder; Disease or Syndrome
T40	DISO 1588 1620	Malformación del tracto urinario
#34	AnnotatorNotes T40	C0158698; Congenital malformation of the urinary system; Congenital Abnormality
T41	DISO 1412 1443	Residuo postmiccional aumentado
T42	CHEM 1687 1699	espermicidas
#35	AnnotatorNotes T42	C0037862; Spermatocidal Agents; Pharmacologic Substance
T43	DISO 1703 1718	Inmunosupresión
#36	AnnotatorNotes T43	C4048329; Immunosuppression; Disease or Syndrome
T44	CHEM 1720 1731	corticoides
#37	AnnotatorNotes T44	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T45	CHEM 1733 1749	inmunosupresores
#38	AnnotatorNotes T45	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T46	DISO 1751 1777	enfermedad inmunosupresora
T47	DISO 1782 1809	Insuficiencia renal crónica
#39	AnnotatorNotes T47	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T48	DISO 1824 1831	Alergia
#40	AnnotatorNotes T48	C1527304; Allergic Reaction; Pathologic Function
T49	CHEM 1863 1882	fármacos en estudio
#41	AnnotatorNotes T49	C0013230; Investigational New Drugs; Pharmacologic Substance
T50	DISO 1834 1846	intolerancia
#42	AnnotatorNotes T50	C0277585; Intolerance to drug; Pathologic Function
T51	DISO 1886 1895	Vaginitis
#43	AnnotatorNotes T51	C0042267; Vaginitis; Disease or Syndrome
T52	PROC 1918 1946	terapia hormonal sustitutiva
#44	AnnotatorNotes T52	C0282402; Hormone replacement therapy; Therapeutic or Preventive Procedure
T53	PROC 1954 1989	tratamiento hormonal genital tópico
T54	ANAT 1975 1982	genital
#45	AnnotatorNotes T54	C0017420; Genitalia; Body Part, Organ, or Organ Component | C0227605; External genitalia; Body Part, Organ, or Organ Component | C0559522; Genital system; Body System
T55	PROC 2005 2027	intervención urológica
T56	PROC 2070 2094	visita de aleatorización
#46	AnnotatorNotes T56	C1512346; Patient Visit; Health Care Activity + C0034656; Randomization; Research Activity
T57	DISO 2098 2119	Enfermedad neoplásica
#47	AnnotatorNotes T57	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T58	PROC 65 85	comparar la eficacia
#48	AnnotatorNotes T58	C1707887; Efficacy Study; Research Activity
T59	ANAT 435 444	Urinarias
#49	AnnotatorNotes T59	C1508753; Urinary system; Body System
T60	ANAT 697 702	orina
#50	AnnotatorNotes T60	C0042036; Urine; Body Substance
T61	ANAT 648 653	orina
#51	AnnotatorNotes T61	C0042036; Urine; Body Substance
T63	DISO 1489 1515	Patología orgánica vesical
T64	ANAT 1535 1542	vesical
#52	AnnotatorNotes T64	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T65	ANAT 1553 1560	vesical
#53	AnnotatorNotes T65	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T66	ANAT 1568 1574	Vejiga
#54	AnnotatorNotes T66	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T67	ANAT 1605 1620	tracto urinario
#55	AnnotatorNotes T67	C0042027; Urinary tract; Body Part, Organ, or Organ Component | C1280341; Entire urinary tract; Body System
T68	ANAT 1796 1801	renal
#56	AnnotatorNotes T68	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T69	CHEM 1926 1934	hormonal
#57	AnnotatorNotes T69	C0019932; Hormones; Hormone
T70	CHEM 1966 1974	hormonal
#58	AnnotatorNotes T70	C0019932; Hormones; Hormone
T71	Date 13 17	2014
T72	LIVB 602 609	Mujeres
#59	AnnotatorNotes T72	C0043210; Woman; Population Group
T73	Age 619 627	≥18 años
T75	Date 725 738	el último año
T77	LIVB 792 800	Paciente
#60	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group
T79	LIVB 857 863	pareja
#61	AnnotatorNotes T79	C0682323; Partner in relationship; Family Group
T80	DEVI 971 995	dispositivo intrauterino
#62	AnnotatorNotes T80	C0021900; Intrauterine Devices; Medical Device
T81	DEVI 997 1000	DIU
#63	AnnotatorNotes T81	C0021900; Intrauterine Devices; Medical Device
T82	DEVI 1003 1016	preservativos
#64	AnnotatorNotes T82	C0009653; Condoms, Male; Medical Device | C0677582; Condoms, Unspecified; Medical Device
T83	Duration 1377 1389	los 12 meses
T84	Time 1420 1433	postmiccional
T87	Duration 1802 1809	crónica
#65	AnnotatorNotes T87	C0205191; chronic; Temporal Concept
T88	LIVB 1905 1913	Paciente
#66	AnnotatorNotes T88	C0030705; Patients; Patient or Disabled Group
T89	Route 1983 1989	tópico
#67	AnnotatorNotes T89	C1522168; Topical Route of Drug Administration; Functional Concept
T90	LIVB 1992 2000	Paciente
#68	AnnotatorNotes T90	C0030705; Patients; Patient or Disabled Group
T91	Date 2028 2036	reciente
T92	Duration 2039 2055	menos de 3 meses
T96	DEVI 1668 1677	diafragma
#69	AnnotatorNotes T96	C0042241; Vaginal contraceptive diaphragm (device); Medical Device
T86	PHYS 1624 1632	Embarazo
#70	AnnotatorNotes T86	C0032961; Pregnancy; Organism Function
T99	PHYS 1649 1658	lactancia
#71	AnnotatorNotes T99	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T74	PROC 821 831	abstenerse
#72	AnnotatorNotes T74	C2042176; abstinence from sexual contact; Therapeutic or Preventive Procedure
T62	LIVB 1218 1226	gérmenes
#73	AnnotatorNotes T62	C0450254; Pathogenic organism; Organism
T76	Dose 1359 1363	1,6%
T78	Dose 1364 1368	2.0%
A1	Status T18 History_of
A2	Status T28 History_of
A3	Status T50 History_of
A4	Status T48 History_of
A5	Status T55 History_of
#74	AnnotatorNotes T8	C1096776; Multicenter Study; Research Activity + C0282462; Phase 4 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C2826345; Parallel Study; Research Activity 
#75	AnnotatorNotes T18	C0042029; Urinary tract infection; Disease or Syndrome
#76	AnnotatorNotes T37	C0005695; Bladder Neoplasm; Neoplastic Process
T85	Quantifier_or_Qualifier 657 668	complicadas
A6	Assertion T85 Negated
#77	AnnotatorNotes T85	C0231242; Complicated; Functional Concept
T93	Neg_cue 654 656	no
R1	Negation Arg1:T93 Arg2:T85	
R2	Location_of Arg1:T59 Arg2:T14	
R3	Location_of Arg1:T17 Arg2:T16	
R4	Used_for Arg1:T3 Arg2:T6	
R5	Used_for Arg1:T5 Arg2:T6	
R6	Before Arg1:T6 Arg2:T7	
R7	Combined_with Arg1:T3 Arg2:T4	
R8	Combined_with Arg1:T10 Arg2:T11	
R9	Used_for Arg1:T10 Arg2:T13	
R10	Used_for Arg1:T12 Arg2:T13	
T94	Observation 201 212	recurrentes
#78	AnnotatorNotes T94	C0679254; Disease recurrence; Finding
R11	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T94	
T95	Observation 445 456	Recurrentes
#79	AnnotatorNotes T95	C0679254; Disease recurrence; Finding
R12	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T95	
T97	Observation 490 503	de repetición
#80	AnnotatorNotes T97	C0679254; Disease recurrence; Finding
R13	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T97	
T98	Observation 562 573	recurrentes
#81	AnnotatorNotes T98	C0679254; Disease recurrence; Finding
R14	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T98	
R15	Before Arg1:T13 Arg2:T14	
R16	Has_Age Arg1:T72 Arg2:T73	
R18	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T85	
T100	Quantifier_or_Qualifier 630 632	≥3
R19	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T100	
T101	Result_or_Value 704 715	>103 UFM/ml
R20	Has_Result_or_Value Arg1:T19 Arg2:T101	
R21	Overlap Arg1:T19 Arg2:T75	
T102	CONC 770 788	inicio del estudio
#82	AnnotatorNotes T102	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R22	Overlap Arg1:T20 Arg2:T102	
T103	Result_or_Value 758 766	negativo
#83	AnnotatorNotes T103	C0205160; Negative; Finding
R23	Has_Result_or_Value Arg1:T20 Arg2:T103	
R24	Experiences Arg1:T77 Arg2:T74	
R25	Experiences Arg1:T79 Arg2:T22	
R26	Experiences Arg1:T77 Arg2:T22	
T104	PROC 918 925	estudio
#84	AnnotatorNotes T104	C0008976; Clinical Trials; Research Activity
R27	Overlap Arg1:T22 Arg2:T104	
R28	Overlap Arg1:T74 Arg2:T104	
R29	Used_for Arg1:T80 Arg2:T24	
R30	Used_for Arg1:T81 Arg2:T24	
R31	Used_for Arg1:T82 Arg2:T24	
R32	Used_for Arg1:T25 Arg2:T24	
R33	Used_for Arg1:T26 Arg2:T24	
T105	Quantifier_or_Qualifier 1160 1166	activa
#85	AnnotatorNotes T105	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R34	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T105	
T106	CONC 1170 1188	empezar el estudio
#86	AnnotatorNotes T106	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R35	Overlap Arg1:T27 Arg2:T106	
R36	Causes Arg1:T62 Arg2:T28	
R37	Used_for Arg1:T31 Arg2:T30	
T107	CONC 1324 1333	inclusión
#87	AnnotatorNotes T107	C1512693; Inclusion; Qualitative Concept
R38	Overlap Arg1:T30 Arg2:T107	
R39	Used_for Arg1:T33 Arg2:T32	
R40	Combined_with Arg1:T33 Arg2:T34	
R41	Has_Dose_or_Strength Arg1:T33 Arg2:T76	
R42	Has_Dose_or_Strength Arg1:T34 Arg2:T78	
R43	Has_Duration_or_Interval Arg1:T33 Arg2:T83	
R44	Has_Duration_or_Interval Arg1:T34 Arg2:T83	
T108	PROC 1401 1408	estudio
#88	AnnotatorNotes T108	C0008976; Clinical Trials; Research Activity
R45	Before Arg1:T32 Arg2:T108	
R46	Overlap Arg1:T41 Arg2:T84	
T109	Result_or_Value 1445 1451	>100cc
R47	Has_Result_or_Value Arg1:T41 Arg2:T109	
R48	Location_of Arg1:T64 Arg2:T37	
R49	Location_of Arg1:T65 Arg2:T38	
R50	Location_of Arg1:T36 Arg2:T63	
R51	Location_of Arg1:T66 Arg2:T39	
R52	Location_of Arg1:T67 Arg2:T40	
R53	Causes Arg1:T44 Arg2:T43	
R54	Causes Arg1:T45 Arg2:T43	
R55	Location_of Arg1:T68 Arg2:T47	
R56	Has_Duration_or_Interval Arg1:T47 Arg2:T87	
T110	Quantifier_or_Qualifier 1896 1902	activa
#89	AnnotatorNotes T110	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R57	Has_Quantifier_or_Qualifier Arg1:T51 Arg2:T110	
R58	Used_for Arg1:T69 Arg2:T52	
R59	Used_for Arg1:T70 Arg2:T53	
R60	Location_of Arg1:T54 Arg2:T53	
R61	Has_Route_or_Mode Arg1:T70 Arg2:T89	
R62	Experiences Arg1:T88 Arg2:T52	
R63	Experiences Arg1:T88 Arg2:T53	
R64	Overlap Arg1:T55 Arg2:T91	
R65	Overlap Arg1:T55 Arg2:T92	
R66	Before Arg1:T55 Arg2:T56	
R67	Experiences Arg1:T90 Arg2:T55	
T111	Quantifier_or_Qualifier 2120 2126	activa
#90	AnnotatorNotes T111	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R68	Has_Quantifier_or_Qualifier Arg1:T57 Arg2:T111	
R69	Causes Arg1:T49 Arg2:T48	
R70	Causes Arg1:T49 Arg2:T50	
T112	Quantifier_or_Qualifier 1810 1820	estadio ?4
R71	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T112	
#91	AnnotatorNotes T46	C5555332; Immunosuppressive Disorder; Disease or Syndrome
R72	Causes Arg1:T46 Arg2:T43	
T113	Quantifier_or_Qualifier 1473 1484	suprapúbica
#92	AnnotatorNotes T113	C0205498; suprapubic approach; Spatial Concept
#93	AnnotatorNotes T35	C0041618; Ultrasonography; Diagnostic Procedure
R74	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T113	
#94	AnnotatorNotes T41	C0749944; URINARY POSTVOID RESIDUAL LARGE; Disease or Syndrome
T114	Observation 1227 1263	resistentes a fosfomicina trometamol
R75	Has_Quantifier_or_Qualifier Arg1:T62 Arg2:T114	
#95	AnnotatorNotes T28	C0851439; Infections - pathogen unspecified; Disease or Syndrome
R76	Used_for Arg1:T3 Arg2:T2	
R77	Used_for Arg1:T5 Arg2:T2	
#96	AnnotatorNotes T26	C5197716; Contraceptive Agents, Hormonal; Pharmacologic Substance
#97	AnnotatorNotes T91	C0332185; Recent; Temporal Concept
#98	AnnotatorNotes T55	C0038913; Urologic Surgical Procedures; Therapeutic or Preventive Procedure
A7	Experiencer T72 Patient
A8	Experiencer T79 Family_member
A9	Experiencer T77 Patient
A10	Experiencer T88 Patient
A11	Experiencer T90 Patient
